tbuckley/cabot-search huggingface dataset:
Cannabis Roots
Authors: Harry C. Shirkey
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The LETTER regarding<i>Cannabis</i>roots (<b>217</b>:1705, 1971) is of great interest. There are a number of cardiotonic-cardiotoxic plants which grow in North America,<sup>1-3</sup>eg,<i>Apocynum cannabinum</i>, family Apocynaceae (Canadian Hemp, Black Indian Hemp); Convallaria<i>majalis</i>, family Liliacea;<i>Evonymus atropurpureus</i>, family Celastraceae (wahoo bark, Indian arrow-wood) and others.<i>Cannabis sativum</i>, family Moraceae (Hemp, Indian Hemp) is a native of other parts of the world but more recently cultivated throughout the world. Too, there are a number of hemps<sup>3</sup>: African bowstring, American, birdseed, black Indian, Canadian, Deccan (i), Indian, Manila, Siam, Sunn, and white Indian. The medical profession was alerted by apocynum "by M.L. Knapp in 1926, although its virtues seem to be known to the aborigines."<sup>1</sup>A number of clinicians had employed it in the treatment of dropsies and presented evidence that it was therapeutically related to digitalis. Wood (<b>43</b>:1953, 1904) showed it
Management of Chronic Obstructive Pulmonary Disease
Authors: Jane F. Desforges, Gary T. Ferguson, Reuben M. Cherniack
Journal: New England Journal of Medicine (1993)

The term "chronic obstructive pulmonary disease" (COPD) refers to a spectrum of chronic respiratory diseases characterized by cough, sputum production, dyspnea, airflow limitation, and impaired gas exchange. Most often associated with cigarette smoking, COPD is estimated to affect at least 15 million Americans and is the fifth leading cause of death in the United States1. Indeed, the death rate has risen by 22 percent in the past decade, and the mortality rate 10 years after diagnosis is greater than 50 percent2. Although many issues remain unresolved, considerable advances have been made in the care of patients with this . . .
Maternal Tobacco Smoke Exposure and Persistent Pulmonary Hypertension of the Newborn
Authors: Cynthia Bearer, Renee K. Emerson, Mary Ann O'Riordan, Esther Roitman, Cedric Shackleton
Journal: Environmental Health Perspectives (1997)

We propose that in utero exposure to tobacco smoke products places a newborn at risk for persistent pulmonary hypertension of the newborn (PPHN). To test this hypothesis, infants with PPHN were identified. Healthy newborns of similar ethnicity were identified as a comparison group. Cord blood cotinine concentrations and maternal questionnaires were obtained. The number of women exposed to tobacco smoke in each group ascertained by questionnaire was borderline significantly different (38.7% vs. 20.5%; p = 0.080). However, more PPHN infants had detectable cotinine in their cord blood (64.5% vs. 28.2%; p = 0.002), and the median cotinine concentrations were significantly higher (5.2 ng/ml vs. 2 ng/ml; p = 0.051) than the comparison infants. Among infants delivered to nonsmoking women, more PPHN infants had detectable cotinine (50% vs. 19%; p = 0.015), and the cotinine concentrations were higher (3.5 ng/ml vs. 1.65 ng/ml; p = 0.022) than the comparison group. We conclude that active and passive smoking during pregnancy is a risk factor for PPHN. Therefore, we recommend that pregnant women cease smoking and avoid environmental tobacco smoke. Key words. cotinine, newborns, passive, persistent pulmonary hypertension, smoking, tobacco smoke pollution.
MYELOID INSUFFICIENCY
Journal: Annals of Internal Medicine (1934)

Article1 January 1934MYELOID INSUFFICIENCYR. GOTTLIEB, M.SC., M.D.R. GOTTLIEB, M.SC., M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-7-7-895 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThere is a group of anemias with a blood picture of an exhausted myeloid system, showing little or no signs of regeneration. The blood picture is that of an anemia, granulocytopenia, and thrombocytopenia. In some of these cases the etiology is known, e.g., arsenic or benzol poisoning, in others the etiological factor cannot be found. In the literature these cases are referred to as "aplastic anemia," "myelophthisic anemia," "aleukia hemorrhagica," etc., but none of these terms properly expresses the character of the condition. We are really dealing with an insufficiency of the myeloid system. A myeloid insufficiency may involve the...Bibliography1. FRANK E: Die Haemorrhagischen Diathesen, Enzyklopaedie d. klin Med. Die Krankheiten d. Blutes u. der Blutbildenen Organe, 1925, ii, Springer, Berlin, p. 289. ROSENTHAL, N.: Hematological aspects of agranulocytosis and other diseases accompanied by extreme leukopenia, Am. Jr. Clin. Path., i, 7-32. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Montreal,*Read before the Annual Clinical Session of the American College of Physicians, February 10, 1933.From the Department of Medicine, McGill University Clinic, Royal Victoria Hospital, Montreal.This research was made possible by a grant from the Banting Research Foundation. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie Panmyelophthise und verwandte Zustände der KnochenmarksinsuffizienzBLOOD DYSCRASIAS SECONDARY TO GOLD: WITH A CASE OF HYPOPLASTIC ANEMIA CURED BY SPLENECTOMY*HENRY J. L. MARRIOTT, B.M. (Oxon.), H. RAYMOND PETERS, M.D., F.A.C.P.Die Milz als Organ des Pfortadersystems und ihr VersagenErkennung und Behandlung der AnämienZur Frage der Myeloischen Reaktion bei Blutkrankheiten 1 January 1934Volume 7, Issue 7Page: 895-902KeywordsAnemiaAplastic anemiaArsenicBloodEtiologyHemorrhageHospital medicineRegenerative medicine Issue Published: 1 January 1934 PDF downloadLoading ...
THE ANTERIOR LOBE OF THE HYPOPHYSIS
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Authors: E Fenwick, B Mr, - Mr, B Miss, W Miss, George Johnison, Mr George, Frederick Page
Journal: BMJ (1889)

Royal Infirmary, Newcastle-upon-Tyne, March 3rd, 1888, suffering from what was supposed to be an ovarian tumour.She stated that ten years ago, while at school, she fell over a form and injured her right side.She was in consequence confined to bed for some weeks with an acute attack of illness, which she was told was an inflammation of the side.Nothing more definite could be learned of this illness.When able to get about again, it was noticed she had a swelling, about the size of an orange, a little below the short ribs on the right side.During the following three years her health was so delicate that she was unable to do much.The swelling in the -sid4 never disappeared, though it varied from time to time in size, but the patient could not state that its size varied with the amount of urine she passed.Five years after the accident, at the age of 16, she went out as a on 20 August
Premedication with Atropine Should Not be Routine
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Informed Consent for Tissue Research
Authors: R. D. Pentz
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4021: A seven-lncRNA signature has a good value of prognosis in esophageal squamous cell carcinoma
Authors: Nuoqing Weng
Journal: Cancer Research (2019)

Abstract Background: Long non-coding RNAs (lncRNAs) were used as prognostic biomarkers in many types of cancer. We aimed to recognize a signature that can forecast the prognosis in patients with esophageal squamous cell carcinoma (ESCC). Method: Using a 2520 probe microarray, we retrospectively analysed lncRNAs expression profiles in 141 samples of ESCC and 81 paired non-cancer specimens that were served as the training set from SUN YAT-SEN University Cancer Center (Guangzhou, China) to evaluate the association between the signature and clinical outcomes. We randomly selected 40 paired tumor tissues and adjacent normal tissues from the above samples for the quantitative RT-PCR to ensure the credibility of microarray data. Then we conducted the quantitative RT-PCR in another 103 samples of ESCC to identify the signature. We applied Kaplan-Meier method and log-rank tests to assess the prognostic power of signature with overall survival (OS) and disease-free survival (DFS). Result: Being differently expression between esophageal squamous cell carcinoma tissues and no-cancer specimens, 338 lncRNAs were selected after filtration. A further analysis were conducted that identified a seven-lncRNA signature in the training set. We calculated the risk score according to the signature and classified ESCC patients as high-risk or low-risk group. Patients in high-risk group had shorter overall survival (HR = 3.555, 95%CI 2.195-5.757, p &amp;lt; 0.0001) and disease-free survival (HR 2.537, 95%CI 1.646-3.909, p &amp;lt; 0.0001) when compared with low-risk group in the training set, and we found the same conclusion in the independent set for OS (HR = 2.662, 95%CI 1.588-4.464, p &amp;lt; 0.0001) and DFS (HR 2.389, 95%CI 1.447-3.946, p &amp;lt; 0.0001). The multivariate Cox proportional hazards regression analysis indicated that the signature is an independent factor for predicting survival. Combing the signature and TNM stage was more powerful than TNM stage alone in prognosing outcomes both in the training set (AUC: 0.778 vs 0.681, p = 0.0127) and in the independent set ((AUC: 0.796 vs 0.713, p = 0.0539). Conclusion: The seven-lncRNA signature might win a place as a valuable prognostic factor in patients survival with ESCC and guide a more individual treatment when cooperating with the TNM stage system. Citation Format: Nuoqing Weng. A seven-lncRNA signature has a good value of prognosis in esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4021.
<i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
Authors: Verena I. Gaidzik, Peter Paschka, Daniela Späth, Marianne Habdank, Claus-Henning Köhne, Ulrich Germing, Marie von Lilienfeld-Toal, Gerhard Held, Heinz-August Horst, Detlef Haase, Martin Bentz, Katharina Götze, Hartmut Döhner, Richard F. Schlenk, Lars Bullinger, Konstanze Döhner
Journal: Journal of Clinical Oncology (2012)

Purpose The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2 mut ) in AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact of TET2 mut in a large cohort of patients with AML in the context of other AML-associated aberrations. Patients and Methods Samples from 783 younger adult patients with AML were analyzed for the presence of TET2 mut (coding exons 3 to 11), and results were correlated with data from molecular genetic analyses, gene-expression profiling, and clinical outcome. Results In total, 66 TET2 mut were found in 60 patients (60 of 783 patients; 7.6%), including missense (n = 37), frameshift (n = 16), and nonsense (n = 13) mutations, which, with one exception, were all heterozygous. TET2 mut were not correlated with distinct clinical features or genetic alterations, except for isocitrate dehydrogenase mutations (IDH mut ) that were almost mutually exclusive with TET2 mut (P &lt; .001). TET2 mut were characterized by only a weak gene-expression pattern, which, nevertheless, reflected TET2 mut -associated biology. TET2 mut did not impact the response to induction therapy and clinical outcome; the combination of patients who exhibited TET2 mut and/or IDH mut revealed shorter overall survival (P = .03), although this association was not independent from known risk factors. Conclusion TET2 mut were identified in 7.6% of younger adult patients with AML and did not impact the response to therapy and survival. Mutations were mutually exclusive with IDH mut , which supported recent data on a common mechanism of action that might obscure the impact of TET2 mut if compared against all other patients with AML.
SHOULD AN EXCEPTION BE MADE AS TO ERGOT?
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Validity of a minimally invasive autopsy for cause of death determination in maternal deaths in Mozambique: An observational study
Authors: Paola Castillo, Juan Carlos Hurtado, Miguel J. Martínez, Dercio Jordao, Lucilia Lovane, Mamudo R. Ismail, Carla Carrilho, Cesaltina Lorenzoni, Fabiola Fernandes, Sibone Mocumbi, Zara Onila Jaze, Flora Mabota, Anelsio Cossa, Inacio Mandomando, Pau Cisteró, Alfredo Mayor, Mireia Navarro, Isaac Casas, Jordi Vila, Maria Maixenchs, Khátia Munguambe, Ariadna Sanz, Llorenç Quintó, Eusebio Macete, Pedro Alonso, Quique Bassat, Jaume Ordi, Clara Menéndez
Journal: PLoS Medicine (2017)

Background Despite global health efforts to reduce maternal mortality, rates continue to be unacceptably high in large parts of the world. Feasible, acceptable, and accurate postmortem sampling methods could provide the necessary evidence to improve the understanding of the real causes of maternal mortality, guiding the design of interventions to reduce this burden. Methods and findings The validity of a minimally invasive autopsy (MIA) method in determining the cause of death was assessed in an observational study in 57 maternal deaths by comparing the results of the MIA with those of the gold standard (complete diagnostic autopsy [CDA], which includes any available clinical information). Concordance between the MIA and the gold standard diagnostic categories was assessed by the kappa statistic, and the sensitivity, specificity, positive and negative predictive values and their 95% confidence intervals (95% CI) to identify the categories of diagnoses were estimated. The main limitation of the study is that both the MIA and the CDA include some degree of subjective interpretation in the attribution of cause of death. A cause of death was identified in the CDA in 98% (56/57) of cases, with indirect obstetric conditions accounting for 32 (56%) deaths and direct obstetric complications for 24 (42%) deaths. Nonobstetric infectious diseases (22/32, 69%) and obstetric hemorrhage (13/24, 54%) were the most common causes of death among indirect and direct obstetric conditions, respectively. Thirty-six (63%) women were HIV positive, and HIV-related conditions accounted for 16 (28%) of all deaths. Cerebral malaria caused 4 (7%) deaths. The MIA identified a cause of death in 86% of women. The overall concordance of the MIA with the CDA was moderate (kappa = 0.48, 95% CI: 0.31–0.66). Both methods agreed in 68% of the diagnostic categories and the agreement was higher for indirect (91%) than for direct obstetric causes (38%). All HIV infections and cerebral malaria cases were identified in the MIA. The main limitation of the technique is its relatively low performance for identifying obstetric causes of death in the absence of clinical information. Conclusions The MIA procedure could be a valuable tool to determine the causes of maternal death, especially for indirect obstetric conditions, most of which are infectious diseases. The information provided by the MIA could help to prioritize interventions to reduce maternal mortality and to monitor progress towards achieving global health targets.
CORRESPONDENCE.
Authors: Paul Paquin
Journal: JAMA (1897)

<h3>Drs. Rochester and J. R. Lemen on Paquin's Serum.</h3> St. Louis, Sept. 29, 1897. <h3>To the Editor:</h3> —Dr. Rochester's letter (Journal American Medical Associationof September 18) in reply to my explanation of his unfair criticism of my work (Journal, August 31) is self condemning. It does not demonstrate that he was justified, and that his efforts to find the truth about sero-therapy in tuberculosis were unbiased. It emphasizes the spirit of reckless indulgence which was manifest in his criticisms of a remedy, which, although not claimed by me to be perfect, is just what I have represented it to be, and was endorsed by many superior physicians. And it again shows a disposition to ruin rather than help those who sacrifice their existence in work to advance the sciences of medicine. I was humiliated to have to publish letters to explain my position, but I was justified; Dr. Rochester
Highlights
Journal: JAMA Dermatology (2017)

Physicians and insurance companies use clinical practice guidelines (CPGs) to make decisions about patient care.These guidelines include recommendations derived from a systematic review of research evidence and careful consideration of benefits and harms associated with medical interventions.In this cross-sectional study of 49 CPG authors, Checketts et al reveal that 40 had received industry payments, and 22 did not accurately disclose their industry relationships.Changes are recommended for panel composition, disclosure policies, and development practices to promote transparency and minimize bias.
Quantitative PCR Deconstruction of Discrepancies between Results Reported by Different Hybridization Platforms
Authors: Federico M. Goodsaid, Roger J. Smith, I.Y. Rosenblum
Journal: Environmental Health Perspectives (2004)

Differences in hybridization platforms used in gene array analysis experiments can lead to significant differences in hybridization results.In this study we used quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to investigate discrepant results between the National Institute of Environmental Health Sciences cDNA and Affymetrix oligo platforms used to evaluate hepatic gene expression changes in rats exposed to methapyrilene.Caldesmon cDNA platform hybridization results showed decreases in gene expression levels for the high-dose methapyrilene 7-day pooled samples compared with their controls.By contrast, the Affymetrix oligonucleotide platform showed increases in expression levels for these samples.Quantitative gene expression measurements provide an explanation for the discrepancies observed for these samples.In the case of caldesmon, there is a 74-base sequence in the cDNA clone that is absent in the Affymetrix sequence.The amplicon based on the cDNA clone shows > 100-fold suppression relative to the day 7 high-dose methapyrilene-pooled control.These data demonstrate the importance of using a "gold standard," such as qRT-PCR to confirm key hybridization results as well as to understand the sources of discrepancies resulting from different hybridization platforms.